Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse
- PMID:15531349
- DOI: 10.1016/j.brat.2003.12.002
Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse
Abstract
Discontinuation of benzodiazepine (BZD) treatment for insomnia can be a difficult task. Cognitive-behavior therapy (CBT) for insomnia, combined with a supervised medication taper, can facilitate withdrawal but there is limited evidence on long-term outcome after discontinuation. The objective of this study was to examine medication-free survival time and predictors of relapse (i.e., resumed BZD hypnotics) over a 2-year period in 47 older adults (mean age 62.1 years) with persistent insomnia and prolonged BZD use (average duration of 18.9 years), who had successfully discontinued BZD following CBT for insomnia, a supervised medication taper program, or a combined approach. The Kaplan-Meier product-limit method was used to estimate survival time, defined as time between end-of-treatment and relapse or end of follow-up. By the end of the 24-month follow-up, 42.6% of the samples had resumed BZD use. Participants in the Combined (33.3%) and Taper (30.8%) groups relapsed significantly less than their counterparts from the CBT group (69.2%). Survival rates at 3 months were 61.5% (CBT), 100% (Taper), and 80.9% (Combined). At 12 months, they were 38.5%, 83.3%, and 70.8%, respectively; and, at 24 months, they were 28.9%, 64.8% and 64.9%, respectively. Mean survival time was significantly longer for both the Taper (18.6 months, SE = 2.1) and Combined groups (12.6 months, SE = 1.4), relative to the CBT group (8.5 months, SE = 1.8). Significant predictors of relapse included treatment condition, end of treatment insomnia severity, and psychological distress. In conclusion, there is a substantial relapse rate following BZD discontinuation among prolonged users. CBT booster sessions might enhance compliance with CBT and prove useful in preventing relapse.
Similar articles
- Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia.Morin CM, Bastien C, Guay B, Radouco-Thomas M, Leblanc J, Vallières A.Morin CM, et al.Am J Psychiatry. 2004 Feb;161(2):332-42. doi: 10.1176/appi.ajp.161.2.332.Am J Psychiatry. 2004.PMID:14754783Clinical Trial.
- Self-efficacy and compliance with benzodiazepine taper in older adults with chronic insomnia.Bélanger L, Morin CM, Bastien C, Ladouceur R.Bélanger L, et al.Health Psychol. 2005 May;24(3):281-7. doi: 10.1037/0278-6133.24.3.281.Health Psychol. 2005.PMID:15898864Clinical Trial.
- Correlates of benzodiazepine use in individuals with insomnia.Morin CM, Bélanger L, Bernier F.Morin CM, et al.Sleep Med. 2004 Sep;5(5):457-62. doi: 10.1016/j.sleep.2004.04.001.Sleep Med. 2004.PMID:15341890
- Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: issues in the treatment of a patient in need.Otto MW, Bruce SE, Deckersbach T.Otto MW, et al.J Clin Psychiatry. 2005;66 Suppl 2:34-8.J Clin Psychiatry. 2005.PMID:15762818Review.
- Cognitive-behavioral approaches to the treatment of insomnia.Morin CM.Morin CM.J Clin Psychiatry. 2004;65 Suppl 16:33-40.J Clin Psychiatry. 2004.PMID:15575803Review.
Cited by
- Psychosocial interventions for benzodiazepine harmful use, abuse or dependence.Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E.Darker CD, et al.Cochrane Database Syst Rev. 2015;2015(5):CD009652. doi: 10.1002/14651858.CD009652.pub2.Cochrane Database Syst Rev. 2015.PMID:26106751Free PMC article.Review.
- Additional Information to Increase Accuracy.Wolter DK.Wolter DK.Dtsch Arztebl Int. 2015 Aug 31;112(35-36):603. doi: 10.3238/arztebl.2015.0603b.Dtsch Arztebl Int. 2015.PMID:26377536Free PMC article.No abstract available.
- Treatment of sleep dysfunction and psychiatric disorders.Becker PM, Sattar M.Becker PM, et al.Curr Treat Options Neurol. 2009 Sep;11(5):349-57. doi: 10.1007/s11940-009-0039-z.Curr Treat Options Neurol. 2009.PMID:19744401
- Beyond Prescriptions Monitoring Programs: The Importance of Having the Conversation about Benzodiazepine Use.Oldenhof E, Anderson-Wurf J, Hall K, Staiger PK.Oldenhof E, et al.J Clin Med. 2019 Dec 4;8(12):2143. doi: 10.3390/jcm8122143.J Clin Med. 2019.PMID:31817181Free PMC article.
- Benzodiazepines II: Waking Up on Sedatives: Providing Optimal Care When Inheriting Benzodiazepine Prescriptions in Transfer Patients.Guina J, Merrill B.Guina J, et al.J Clin Med. 2018 Jan 30;7(2):20. doi: 10.3390/jcm7020020.J Clin Med. 2018.PMID:29385766Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical